Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a common diabetes pill improve life for kidney dialysis patients?

NCT ID NCT05786443

First seen Dec 04, 2025 · Last updated Apr 24, 2026 · Updated 14 times

Summary

This study is testing whether empagliflozin, a drug used for diabetes, is safe and helpful for people who have just started hemodialysis for end-stage kidney disease. About 60 adults will receive either the drug or a placebo for 12 weeks. Researchers will measure changes in body fluid levels, urine output, and blood pressure to see if the drug can improve fluid balance and heart health.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END STAGE RENAL DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Brigham and Women's Hospital

    RECRUITING

    Boston, Massachusetts, 021215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • NYU Langone Health

    RECRUITING

    New York, New York, 10016, United States

    Contact

Conditions

Explore the condition pages connected to this study.